Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6P11

Structure of spastin AAA domain (T692A mutant) in complex with JNJ-7706621 inhibitor

Summary for 6P11
Entry DOI10.2210/pdb6p11/pdb
DescriptorDrosophila melanogaster Spastin AAA domain, SULFATE ION, 4-({5-amino-1-[(2,6-difluorophenyl)carbonyl]-1H-1,2,4-triazol-3-yl}amino)benzenesulfonamide, ... (5 entities in total)
Functional Keywordsinhibitor, complex, aaa protein, isomerase-isomerase inhibitor complex, isomerase/isomerase inhibitor
Biological sourceDrosophila melanogaster (Fruit fly)
Total number of polymer chains1
Total formula weight34899.60
Authors
Pisa, R.,Cupido, T.,Kapoor, T.M. (deposition date: 2019-05-17, release date: 2019-07-24, Last modification date: 2023-10-11)
Primary citationPisa, R.,Cupido, T.,Steinman, J.B.,Jones, N.H.,Kapoor, T.M.
Analyzing Resistance to Design Selective Chemical Inhibitors for AAA Proteins.
Cell Chem Biol, 26:1263-, 2019
Cited by
PubMed Abstract: Drug-like inhibitors are often designed by mimicking cofactor or substrate interactions with enzymes. However, as active sites are comprised of conserved residues, it is difficult to identify the critical interactions needed to design selective inhibitors. We are developing an approach, named RADD (resistance analysis during design), which involves engineering point mutations in the target to generate active alleles and testing compounds against them. Mutations that alter compound potency identify residues that make key interactions with the inhibitor and predict target-binding poses. Here, we apply this approach to analyze how diaminotriazole-based inhibitors bind spastin, a microtubule-severing AAA (ATPase associated with diverse cellular activities) protein. The distinct binding poses predicted for two similar inhibitors were confirmed by a series of X-ray structures. Importantly, our approach not only reveals how selective inhibition of the target can be achieved but also identifies resistance-conferring mutations at the early stages of the design process.
PubMed: 31257183
DOI: 10.1016/j.chembiol.2019.06.001
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.15 Å)
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon